Pfizer’s Co-Developed Sickle Cell Drug Gets Orphan Status in Europe and 2 Other Hot Stocks to Watch

Pfizer Inc. (NYSE:PFE): Current price $28.55

GlycoMimetics has reported that the European Medicines Agency has awarded orphan drug status in the European Union for GMI-1070, which is being developed in partnership with Pfizer in Sickle Cell Disease. The drug designation for GMI-1070 (rivipansel sodium) is for the treatment of vaso-occlusive crisisin patients who are suffering from sickle cell disease. Orphan drug designation in the European Union is given to products that are created for the diagnosis, prevention, or treatment of rare diseases which are life-threatening or very serious.

pfe-20130913